Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.3.1.21 (CPT)
 4,580 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The aim of the investigation was to throw light on the question whether drugs other than antibiotics and chemotherapeutic agents exert an antimicrobial effect. In order to elucidate this, the antimicrobial effect of selected psychotherapeutic drugs and their stereo-isomeric analogues was studied. The development of psychotherapeutic drugs from aniline dyes has been reviewed against the background of its history considered as a scientific idea. It is demonstrated that psychotherapeutic drugs have an antimicrobial effect. Psychotherapeutic drugs show antimicrobial activity at high concentrations. Stereo-isomeric analogues of known psychotherapeutic drugs also have an antimicrobial effect. The selectivity of the various stereo-isomeric compounds depends on which microorganism and which chemical compound is investigated. Synergism is found between psychotherapeutic drugs (CPZ) and penicillin in vitro, and between a non-neuroleptic stereo-isomeric compound trans-CPT and penicillin in vivo, using infected mice as material. The antibacterial activity of psychotherapeutic drugs is independent of the antihistaminic, antihypersecretory, neuroleptic and antidepressant effect of these drugs. The examples chosen of investigations of the antimicrobial effect of psychotherapeutic drugs in vitro and in vivo lead to the conclusion and to the perspectives in the present study. Namely, the need for a general theory of the interplay between host organism, microorganisms and drugs. This proposition is based on a concern to argue against the view that the prokaryotic effect of eukaryote-directed drugs is without major significance, either for scientific research or for clinical treatment.
 ...
PMID:The antimicrobial activity of psychotherapeutic drugs and stereo-isomeric analogues. 218 4

We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1% had malignancy as an underlying disease. SBT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients and 21.4% (3 patients), respectively. A significant difference (p < 0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simultaneously in 20 patients. Mild or moderate side effect (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.
 ...
PMID:[Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections]. 965 4